Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme system in gastric parietal cells.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Duoen_al ulcers
* Gastric ulcers
* Zollinger-Ellison syndrome
* *Helicobacter pylori* eradication (in combination regimens)
### Adult Dosing
* **GERD:** 20 mg or 40 mg once daily. Duration of therapy varies.
* **Erosive Esophagitis:** 40 mg once daily for up to 8 weeks. For patients who have not healed, an additional 8 weeks may be considered.
* **Duoen_al Ulcers:** 40 mg once daily for up to 4 weeks.
* **Gastric Ulcers:** 40 mg once daily for up to 4 weeks.
* **Zollinger-Ellison Syndrome:** 40 mg twice daily. Doses may be increased as clinically indicated. The maximum recommended dose is 240 mg daily.
* ***H. pylori* Eradication:** 40 mg twice daily for 7-14 days in combination with clarithromycin and amoxicillin or metronidazole.
### Pediatric Dosing
* **GERD and Erosive Esophagitis (1 month to 5 years):** 1.1 mg/kg to 2.2 mg/kg orally once daily. Do not exceed 20 mg daily.
* **GERD and Erosive Esophagitis (5 years and older):** 20 mg or 40 mg once daily.
* **Note:** Dosing in neonates and infants younger than 1 month is not established due to safety concerns. Consult specific pediatric guidelines.
### Dose Adjustments
* **Hepatic Impairment:** For severe hepatic impairment, consider a dose reduction to 20 mg once daily.
### Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
### Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia (can be asymptomatic or manifest as tetany, seizures, arrhythmias), vitamin B12 deficiency, potential for fundic gland polyps. Acute interstitial nephritis.
### Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** PPIs can decrease the absorption of drugs requiring an acidic environment (e.g., ketoconazole, itraconazole, iron salts, cyanocobalamin, mycophenolate mofetil).
* **Methotrexate:** PPIs may increase and prolong serum levels of methotrexate.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Monitor for potential increased levels of drugs metabolized by this enzyme (e.g., clopidogrel, voriconazole).
* **Atazanavir and Ritonavir:** Concomitant use is generally not recommended.
### Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Monitor serum magnesium levels periodically, especially in patients on long-term therapy or concomitant diuretic use.
* Consider monitoring vitamin B12 levels with long-term therapy.
* Evaluate bone density in patients at risk for osteoporosis.
### Clinical Pearls
* Pantoprazole is generally administered 30-60 minutes before a meal.
* For *H. pylori* eradication, ensure complete adherence to the multi-drug regimen.
* Long-term PPI use is associated with increased risk of fractures, *C. difficile* infection, hypomagnesemia, and vitamin B12 deficiency. Use the lowest effective dose for the shortest duration necessary.
* IV administration may be considered when oral therapy is not possible.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete details.*
